Methodology and Sources This analysis is based on publicly available sources as of December 26, 2025: FDA communications: Compounding safety alerts, prescribing information, and regulatory guidance Novo Nordisk announcements: Wegovy pill approval, OASIS 4 trial results, pricing disclosures Independent reporting and primary sources: ABC News coverage and Novo Nordisks announcement on December 22, 2025 FDA oral Wegovy approval MEDVi terms and disclosures: Platform structure, pricing, and regulatory disclaimers Key Sources Cited: ABC News: "FDA approves Wegovy pill for weight loss" (December 22, 2025) Novo Nordisk: Official press release on FDA approval and OASIS 4 trial data (December 22, 2025) FDA Safety Communications: 20242025 alerts on compounded semaglutide dosing errors All regulatory references are based on FDA publications and third-party reporting available at the time of publication
Some medications like liraglutide, dulaglutide, and semaglutide have proven cardiovascular benefits, along with other benefits such as appetite suppression, weight management, and glycemic control
What youll learn Well explain how oral and injectable semaglutide differ in how theyre taken, how they work, and how they might fit your lifestyle and goals
Our program is designed to support your health goals while also providing the financial flexibility to utilize your HSA or FSA funds
